US Capitol Capsule: Allies offer Alzheimer’s advice: Combo attack
This article was originally published in Scrip
At the end of a three-day meeting last week in Washington, high-ranking US government officials joined patient groups and academic leaders advocating for greater Alzheimer's disease research and better strategies for drug development in declaring that combination therapies, which have become the hallmark for treating HIV/AIDS, many cancers and tuberculosis, should be pursued as the new plan of attack against the progressive fatal neurodegenerative disorder, which robs people of their memories, independence and identity.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.